<?xml version="1.0" encoding="UTF-8"?>
<p>Treatment of HBV-GN remains a challenge for clinicians, the use of steroids or immunity inhibitors is still controversial because of the risk of activating viral infections, so the mainstay of treatment continues to be antiviral therapy. Several drugs are now available for the treatment of chronic HBV infection and are mainly one of two types: nucleos (t) ide analogs (NAs), such as lamivudine, adefovir, entecavir, telbivudine, and tenofovir, and interferons (IFNs)[
 <xref rid="pone.0227532.ref003" ref-type="bibr">3</xref>]. However, their efficacy and safety remain poorly established and uncertain.
</p>
